Clinical trials: Advanced Adenocarcinoma
Hepatocellular Carcinoma
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma…
- Trial name
- CheckMate 9DW (NCT04039607)
- Testing
- Nivolumab, Ipilimumab, Sorafenib
- Where
- 210 sites in United States, Argentina and 24 more
- Volunteers
- 732 people
- Sponsor
- Bristol-Myers Squibb
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
This phase II trial studies the effects of temsirolimus in treating patients with cervical cancer that cannot be cured by standard therapy.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT01026792
- Testing
- Temsirolimus, Laboratory Biomarker Analysis
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-paclitaxel in the second-line treatment of patients with advanced…
- Trial name
- NCT07139587
- Testing
- Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingxia Li
Hepatocellular Carcinoma
Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
There are limited treatment options for patients with unresectable hepatocellular carcinoma (HCC) who failed to the combination therapy with targeted agents plus anti-PD-1/PD-L1.
- Trial name
- NCT04994236
- Testing
- Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Hui-Chuan Sun
Clear Cell Renal Cell Carcinoma
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell…
- Trial name
- NCT04169711
- Testing
- ARO-HIF2
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Arrowhead Pharmaceuticals
Clear Cell Renal Cell Carcinoma
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC.
- Trial name
- NCT07564232
- Testing
- Cyclophosphamide, Fludarabine, LNK001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Trial name
- NCT07673887
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 8 sites in United States, China and 2 more
- Volunteers
- 570 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Rectal Cancer
Preoperative Panitumumab and Radiotherapy in Rectal Cancer
The purpose of this study is to investigate the activity of panitumumab in combination with standard preoperative radiotherapy in locally advanced rectal cancer, followed by complete surgery and adjuvant chemotherapy.
- Trial name
- PrePaRad (NCT00973193)
- Testing
- panitumumab
- Where
- 8 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hepatocellular Carcinoma
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT06363006
- Testing
- TKI+Cardunilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma, Liver Cancer
SU011248 in Advanced Hepatocellular Carcinoma
The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer.
- Trial name
- NCT00361309
- Testing
- SU011248
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Bladder Cancer, Urethral Cancer
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002684
- Testing
- cisplatin, ifosfamide, paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignancies, Oncology
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
- Conditions
- Advanced Malignancies, Oncology, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT07504263
- Testing
- RP-001
- Volunteers
- 66 people
- Sponsor
- Recurv Pharma Inc
Digestive Cancer, Metastatic Colorectal Cancer
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic…
- Conditions
- Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
- Trial name
- TARGETMONITO (NCT05443087)
- Testing
- Blood sampling to build population pharmacokinetics model
- Where
- 29 sites in France
- Volunteers
- 330 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Sorafenib is the standard therapy for advanced liver cancer but often shows dose-limiting toxicities with the need to reduce the applied dose of the compound.
- Trial name
- NCT01335074
- Testing
- Temsirolimus + Sorafenib
- Where
- Germany
- Sponsor
- Philipps University Marburg
Hepatocellular Carcinoma
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma.
- Trial name
- NCT06710223
- Testing
- SD-101, Cryotherapy, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Hepatocellular Carcinoma, Liver Neoplasms
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
This single-center, prospective phase II clinical trial evaluates the safety and therapeutic efficacy of combining carbon ion radiotherapy with the standard first-line regimen of atezolizumab and bevacizumab in patients with…
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Carcinoma, Hepatocellular
- Trial name
- NCT07246668
- Testing
- Carbon Ion Radiotherapy Atezolizumab Bevacizumab
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Yonsei University
Advanced Hepatocellular Carcinoma
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of Intravenous CD-801 treatment in subjects with advanced hepatocellular carcinoma(HCC).
- Trial name
- NCT06418659
- Testing
- CD-801
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Changzheng Hospital
Colorectal Cancer
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00975897
- Testing
- bevacizumab, cetuximab, fluorouracil
- Where
- 3 sites in United Kingdom
- Volunteers
- 3,240 people
- Sponsor
- Medical Research Council
Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung
- Trial name
- NCT00042679
- Testing
- Gemcitabine, Carboplatin, LY900003
- Where
- 11 sites in United States
- Sponsor
- Eli Lilly and Company
Liver Cancer
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00006010
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 17 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology